The Disruptive Technologies Innovation Fund (DTIF) is an Irish government-backed, €500 million fund, overseen by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland.

It aims to accelerate industrial research and experimental development (TRL 3–9) through collaborative consortia of at least three, involving at least one SME and another enterprise partner.

Applications are assessed against four key criteria: disruptiveness, quality of approach, economic impact and sustainability, and collaboration strength.

The total funding awarded is now up to €455 million across 118 projects and 7 DTIF calls.

This substantial investment positions Ireland as a hub for disruptive technology development and R&D, attracting international attention and fostering a thriving innovation ecosystem that benefits from strong government backing and industry collaboration.

Winners at Call 7

Myriad is proud to say that seven projects that we supported were funded in Call 7, including a record-breaking €12 million project, the DTIF’s largest award since the programme’s inception in 2018.

The following projects were funded by Myriad:

• DUO MAX: A device tailored to patients with failing tricuspid valves are unsuitable for conventional repair.
  • DTIF Award: €7.1 million
  • Consortium: CroíValve; BlueAcre Technologies; Royal College of Surgeons; Trinity College Dublin
• ECORE: A minimally invasive delivery system for targeted therapies in vascular disorders and cancer.
  • DTIF Award: €6.0 million
  • Consortium: LaNua Medical; Integer Holdings; University College Dublin (UCD)
• FutureLives: Aims to enhance nutrient use efficiency in farming, reduce greenhouse gas emissions, and build climate-resilient agricultural systems.
  • DTIF Award: €2.9 million
  • Consortium: GlasPort Bio Ltd; GlasPort Rumen Tech Ltd; Agri-IOT Ltd; University of Galway
• N-LIFT: Developing the world's first cell bank of cancer-killing and immunomodulatory white blood cells to deliver a portfolio of cell therapies for solid tumour indications.
  • DTIF Award: €11.9 million
  • Consortium: LlfT Biosciences (lead); HookeBio; University of Galway
• ProVascTec: Uses cell therapy and regenerative medicine to stimulate the formation of new microvasculature.
  • DTIF Award: €2.5 million
  • Consortium: ProVascTec; Arrotek; University College Cork (UCC)
• PIONEER: is a repositionable left atrial appendage occluder designed for high-risk atrial fibrillation patients not well served by current options.
  • DTIF Award: €6.3 million
  • Consortium: AuriGen Medical Ltd; Integer Holdings (Brivant & Aran Biomedical divisions); Atlantic Technological University
• Ventripump: is a minimally invasive cardiac assist device project developing a next-generation implantable pump to support patients with advanced heart failure.
  • DTIF Award: €9.3 million
  • Consortium: CardiacBooster Ltd; FIRE1 (Foundry Innovation & Research 1 Ltd); Integer Holdings (Brivant)

You can find more information on these projects here.

Preparing for the Call

We’re expecting DTIF Call 8 to come out in the next few months, but interested parties should start preparing early to make the application as smooth as possible.

This involves:

• Understanding the specific criteria and objectives of the fund.
• Building strong consortia or partnerships.
• Refining project proposals to highlight innovation, market potential, and alignment with strategic goals.

Utilising Available Resources

The DTIF offer various resources to aid applicants. Webinars, guidance documents, and past success stories can provide invaluable insights into the application process and expectations.

Previous DTIF documentation, including prior winners, can be found here.

Working with Myriad

At Myriad, we’ve been working with winning DTIF proposals since Call 1. Our market-leading team is ready to put your company front and centre, aiming to secure the R&D grants in Ireland that elevates your innovation strategy to the next level.

Myriad's success in securing funding stems from our long-standing relationships with some of Ireland's most innovative companies, particularly in the medical technology sector. We recognise that each project represents years of research, development, and vision from dedicated teams working to solve some of society's most pressing challenges. Our role is to effectively communicate this vision and demonstrate how proposed solutions align with DTIF objectives and assessment criteria.

With millions of euros on the line, it’s worth having a chat with the experts. Get in touch with Myriad’s team and find out if your project could be funded.